Download PDF
Thromb Haemost 1997; 77(04): 730-734
DOI: 10.1055/s-0038-1656042
Fibrinolysis
Schattauer GmbH Stuttgart

Plasminogen Activator Inhibitor-1 (PAI-1) 4G/5G Promoter Polymorphism and Levels in Subjects with Cerebrovascular Disease

Andrew J Catto
The Unit of Molecular Vascular Medicine, Research School of Medicine, University of Leeds, Leeds General Infirmary, Leeds, United Kingdom
,
Angela M Carter
The Unit of Molecular Vascular Medicine, Research School of Medicine, University of Leeds, Leeds General Infirmary, Leeds, United Kingdom
,
Max Stickland
The Unit of Molecular Vascular Medicine, Research School of Medicine, University of Leeds, Leeds General Infirmary, Leeds, United Kingdom
,
John M Bamford
1   Department of Neurology, St James’s University Hospital, Leeds, United Kingdom
,
J Andrew Davies
The Unit of Molecular Vascular Medicine, Research School of Medicine, University of Leeds, Leeds General Infirmary, Leeds, United Kingdom
,
Peter J Grant
The Unit of Molecular Vascular Medicine, Research School of Medicine, University of Leeds, Leeds General Infirmary, Leeds, United Kingdom
› Author Affiliations
Further Information

Publication History

Received 11 June 1996

Accepted after resubmission 02 December 1996

Publication Date:
11 July 2018 (online)

  PDF Download  Permissions and Reprints

Summary

The exact role of the fibrinolytic system in the pathogenesis of stroke remains to be established. Elevated circulating levels of plasminogen activator inhibitor-1, the principle inactivator of the fibrinolytic system, have been related to the development of myocardial infarction. There is evidence that a polymorphism in the promoter region of the PAI-1 gene is associated with circulating PAI-1 levels.

We studied a common single nucleotide insertion/deletion (4G/5G) polymorphism by PCR in 558 patients with stroke, the pathological type of which was established by cranial computed tomography, and in 172 controls. 4G/5G genotype and PAI-1 activity were investigated in relation to 1) stroke type and 2) mortality occurring within four weeks, three months and six months of the stroke.

No difference in genotype frequency was observed when all cases of stroke were compared with controls nor between the clinically determined subtypes of cerebral infarction. PAI-1 activity was significantly higher in patients with stroke (n = 245) both at presentation (11.6 U/ml) and after three months (11.8 U/ml), in paired samples, than in control subjects (8.8 U/ml, p <0.0001). Thirty-seven (6.2%), 86 (14.5%) and 122 (20.5%) patients had died within one, three and six months of admission, respectively. PAI-1 activity was independently associated with all-cause mortality at one and three months after stroke (p = 0.02 and p = 0.03 respectively), but not after six months.

In this population the 4G/5G promoter polymorphism is not associated with an increased risk of stroke. PAI-1 levels were elevated at the time of acute stroke which persisted after three months. PAI-1 level but not genotype was associated with early mortality following stroke.

 

  • References

  • 1 Ridker PM, Hennekens CH. Hemostatic risk factors for coronary heart disease. Circulation 1991; 83: 1098-100
    CrossrefPubMedGoogle Scholar
  • 2 Meade TW, Mellows S, Brozovic M, Miller GJ, Chakrabarti RR, North WR, Haines AP, Stirling Y, Imeson JD, Thompson SG. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet 1986; 02: 533-537
    PubMedGoogle Scholar
  • 3 Hamsten A, Walldius G, De FaireU, Dahlen G, Szamosi A, Landou C, Blombäck M, Wiman B. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; 02: 3-9
    PubMedGoogle Scholar
  • 4 Brockmann MJ, Schwendemann G, Stief TW. Plasminogen activator inhibitor in acute stroke. Mol Chem Neuropathol 1991; 14: 143-150
    CrossrefPubMedGoogle Scholar
  • 5 Margaglione M, Minno G, Grandone E, Vecchione G, Celentano E, Cappucci G, Grilli M, Simone P, Panico S, Mancini M. Abnormally high circulation levels of tissue plasminogen activator and plasminogen activator inhibitor-1 in patients with a history of ischemic stroke. Arter Thromb 1994; 14: 1741-1745
    PubMedGoogle Scholar
  • 6 Glueck CJ, Rorick MH, Schmerler M, Anthony J, Feibel J, Bashir M, Glueck HI, Stroop D, Wang Y, Tracy TM. Hypofibrinolytic factors and atherogenic risk factors for stroke. J Lab Clin Med 1995; 125: 319-325
    PubMedGoogle Scholar
  • 7 Kempter B, Peinemann A, Biniasch o, Haberl RL. Decreased fibrinolytic stimulation by a short-term venous occlusion test in patients with cerebrovascular disease. Thromb Res 1995; 79: 363-368
    CrossrefPubMedGoogle Scholar
  • 8 Fisher M, Francis R. Altered coagulation in cerebral ischaemia. Platelet, thrombin and plasmin activity. Arch Neurol 1990; 47: 1075-1079
    CrossrefPubMedGoogle Scholar
  • 9 Ridker PM, Hennekens CH, Stampfer MJ, Manson JE, Vaughan DE. Prospective study of endogenous tissue plasminogen activator and risk of stroke. Lancet 1994; 343: 940-943
    CrossrefPubMedGoogle Scholar
  • 10 Dawson S, Hamsten A, Wiman B, Henney A, Humphries S. Genetic variation at the plasminogen activator inhibitor-1 locus is associated with altered levels of plasma plasminogen activator inhibitor-1 activity. Arter Thromb 1991; 11: 183-190
    PubMedGoogle Scholar
  • 11 Eriksson P, Kallin B, Van’ T, Hooft FM, Bavenholm P, Hamsten A. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Nat Acad Sci USA 1995; 92: 1851-1855
    CrossrefPubMedGoogle Scholar
  • 12 Mansfield MW, Stickland MH, Grant PJ. Environmental and genetic factors in relation to elevated circulating levels of plasminogen activator inhibitor-1 in caucasian patients with non-insulin-dependent diabetes mellitus. Thromb Haemost 1995; 74: 842-847
    Article in Thieme ConnectPubMedGoogle Scholar
  • 13 Panahloo A, Mohamed-Ali V, Lane A, Green F, Humphries SE, Yudkin JS. Determinants of plasminogen activator inhibitor 1 activity in treated NIDDM and its relation to a polymorphism in the plasminogen activator inhibitor 1 gene. Diabetes 1995; 44: 37-42
    CrossrefPubMedGoogle Scholar
  • 14 Hantano S. Experience from a multicentre stroke register: a preliminary report. Bull World Health Organ 1976; 54: 541-553
    PubMedGoogle Scholar
  • 15 Rose G, McCartney P, Reid DD. Self-administration of a questionnaire on chest pain and intermittent claudication. British Journal of Preventive and Social Medicine 1977; 31: 42-48
    PubMedGoogle Scholar
  • 16 WHO MONICA Project. WHO MONICA Project: assessing CHD mortality and morbidity. Int J Epidemiol 1989; 18: S38-S45
    PubMedGoogle Scholar
  • 17 Bamford J, Sandercock P, Dennis M, Bum J, Warlow C. Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet 1991; 337: 1521-1526
    CrossrefPubMedGoogle Scholar
  • 18 Mansfield MW, Stickland MH, Carter AM, Grant PJ. Polymorphisms of the plasminogen activator inhibitor-1 gene in type 1 and type 2 diabetes, and in patients with diabetic retinopathy. Thromb Haemost 1994; 71: 731-736
    Article in Thieme ConnectPubMedGoogle Scholar
  • 19 Kruithof E. Plasminogen activators: a review. Enzyme 1988; 40: 113-121
    CrossrefPubMedGoogle Scholar
  • 20 Juhan-Vague I, Aillaud MF, DeCock FPC, Amaud C, Serradimigni A, Collen P, Davidson JF, Donati MB, Coccheri S. (eds). Progress in fibrinolysis. Edinburgh: Churchill Livingstone. 1985. The fast-acting inhibitor of tissue-type plasminogen activator is an acute phase reactant pp 146-149
    Google Scholar
  • 21 Schneiderman J, Sawdey MS, Keeton MR, Bordin GM, Bernstein EF, Dilley RB, Loskutoff DJ. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Nat Acad Sci USA 1992; 89: 6998-7002
    CrossrefPubMedGoogle Scholar
  • 22 Anonymous. ECAT angina pectoris study: baseline associations of haemostatic factors with extent of coronary arteriosclerosis and other coronary risk factors in 3000 patients with angina pectoris undergoing coronary angiography. Eur Heart J 1993; 14: 08-17
    PubMedGoogle Scholar
  • 23 Dennis MS, Bum JPS, Sandercock PA, Bamford J, Wade DT, Warlow CP. Long term survival after first-ever stroke: The Oxfordshire Community Stroke Project. Stroke 1993; 24: 796-800
    CrossrefPubMedGoogle Scholar
  • 24 Jansson JH, Nilsson TK, Johnson O. von Willebrand factor in plasma: a novel risk factor for recurrent myocardial infarction and death. Br Heart J 1991; 66: 351-355
    CrossrefPubMedGoogle Scholar
  • 25 Aronson DC, Ruys T, van Bockel JH. A prospective study of risk factors in young adults with arterial occlusive disease. Eur J Vase Surg 1989; 03: 227-232
    CrossrefPubMedGoogle Scholar
  • 26 Falk G, Almquist A, Nordenhern A, Svensson H, Wiman B. Allele specific PCR for the detection of a sequence polymorphism in the promoter region of the plasminogen-activator inhibitor-1 (PAI-1) gene. Fibrinolysis 1995; 09 (03) 170-174
    PubMedGoogle Scholar
  • 27 Ossei-Gerning N, Mansfield MW, Stickland MH, Wilson IJ, Grant PJ. Plasminogen activator inhibitor-1 (PAI-1) promoter 4G/5G genotype and levels in relation to a history of myocardial infarction in patients characterised by coronary angiography. Arterioscler Thromb Vase Biol. 1996. In press
    Google Scholar
  • 28 Ye S, Green FR, Scarabin PY, Nicaud V, Bara L, Dawson SJ, Humphries SE, Evans A, Luc G, Cambou JP, Arveiler D, Henney AM, Cambien F. The 4G/5G genetic polymorphism in the promoter of the plasminogen activator inhibitor-1 (PAI-1) gene is associated with differences in plasma PAI-1 activity but not with risk of myocardial infarction in the ECTIM study. Thromb Haemost 1995; 74: 837-841
    Article in Thieme ConnectPubMedGoogle Scholar
  • 29 Mansfield MW, Stickland MH, Grant PJ. Plasminogen activator inhibitor-1 (PAI-1) promoter polymorphism and coronary artery disease in Non-Insulin-Dependent Diabetes. Thromb Haemost 1995; 74: 1032-1034
    Article in Thieme ConnectPubMedGoogle Scholar